Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.61 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.52 |
| ▸ | SLC5A2 | P31639 | 3/20 | 0.47 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.47 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.41 |
| ▸ | ESR1 | P03372 | 6/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2579031 | 0.93 | KEAP1 (0.58) | KEAP1HSPA5SLC5A2SLC5A1BCL2 | |
| SCHEMBL30616875 | 0.82 | KEAP1 (0.86) | KEAP1HSPA5BCL2BCL2L1CYP3A4 | |
| SCHEMBL9776607 | 0.82 | KEAP1 (0.86) | KEAP1HSPA5BCL2BCL2L1CYP3A4 | |
| SCHEMBL4859648 | 0.77 | KDM4C (0.45) | KEAP1SLC5A2SLC5A1ESR2ESR1 | |
| SCHEMBL29506902 | 0.77 | KEAP1 (1.00) | KEAP1HSPA5BCL2BCL2L1ESR2 | |
| SCHEMBL68653 | 0.77 | KEAP1 (1.00) | KEAP1HSPA5BCL2BCL2L1ESR2 | |
| SCHEMBL8925742 | 0.77 | KEAP1 (0.76) | KEAP1HSPA5BCL2BCL2L1CYP3A4 | |
| SCHEMBL27698448 | 0.77 | LTA4H (0.56) | SLC5A2SLC5A1CYP3A4CYP2D6 | |
| SCHEMBL30335116 | 0.76 | KEAP1 (0.75) | KEAP1HSPA5BCL2BCL2L1CYP3A4 | |
| SCHEMBL87816 | 0.76 | KEAP1 (0.75) | KEAP1HSPA5BCL2BCL2L1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048897-B2 | Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-01 | — | — | US | disclosed |
| CN-101010276-B | Cyclohexane derivative, prodrug thereof, salt thereof, and therapeutic agent for diabetes containing same | CHUGAI PHARMACEUTICAL CO LTD | 2011-01-12 | — | — | CN | disclosed |
| US-20080318874-A1 | Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-12-25 | — | — | US | disclosed |
| CN-101010276-A | Novel cyclohexane derivative, prodrug thereof, salt thereof, and therapeutic agent for diabetes containing the same | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2007-08-01 | — | — | CN | disclosed |
| EP-1783110-A1 | NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318874-A1 | Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes | SLC5A1, GPR119, SLC5A2 | KEAP1 901/4885HSPA5 2445/4885SLC5A2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.